ArticleKidney3602020
Interferon Regulatory Factor-5 in Resident Macrophage Promotes Polycystic Kidney Disease.
Open access · diamondAbstract read
In one paragraph
Article in Kidney360, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- The Role of Immune Cells as Modulators of Progression in Polycystic Kidney Disease: A Systematic Review.Kidney360 · 2026Pooled it
- Article
- Spatially patterned kidney assembloids recapitulate progenitor self-assembly and enable high-fidelity in vivo disease modeling.Cell stem cell · 2025Article
- Antiproliferative effects of dihydrotanshinone I on autosomal dominant polycystic kidney disease via immunomodulation.The Journal of pharmacology and experimental therapeutics · 2025Article
- Wheat-Based Protein Slows Disease Progression in Pkd1 Knockout Mice.Function (Oxford, England) · 2025Article
- Integrated single-cell transcriptomic map of pig kidney cells across various periods and anatomical sites.Zoological research · 2025Article
- The impact of maternal obesity on polycystic kidney disease progression in a mouse model.American journal of physiology. Renal physiology · 2025Article
- Intestinal barrier function declines during polycystic kidney disease progression.American journal of physiology. Renal physiology · 2025Article
- Rapamycin-encapsulated nanoparticle delivery in polycystic kidney disease mice.Scientific reports · 2024Article
- Multi-Omic Analysis Reveals Genetic Determinants and Therapeutic Targets of Chronic Kidney Disease and Kidney Function.International journal of molecular sciences · 2024Article
- Novel anti-inflammatory effects of the IL-1 receptor in kidney myeloid cells following ischemic AKI.Frontiers in molecular biosciences · 2024Article
- Severity of polycystic kidney disease revealed by multiparametric MRI.Magnetic resonance in medicine · 2023Article
- A macrophage-endothelial immunoregulatory axis ameliorates septic acute kidney injury.Kidney international · 2023Article
- Review of the Use of Animal Models of Human Polycystic Kidney Disease for the Evaluation of Experimental Therapeutic Modalities.Journal of clinical medicine · 2023Review
- The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression.JCI insight · 2023Article
- Accelerated cystogenesis by dietary protein load is dependent on, but not initiated by kidney macrophages.Frontiers in medicine · 2023Article
- A kidney resident macrophage subset is a candidate biomarker for renal cystic disease in preclinical models.Disease models & mechanisms · 2023Article
- Immunosuppression by Mycophenolate Mofetil Mitigates Intrarenal Angiotensinogen Augmentation in Angiotensin II-Dependent Hypertension.International journal of molecular sciences · 2022Article
- Macrophage Heterogeneity in Kidney Injury and Fibrosis.Frontiers in immunology · 2021Review
- Role of chemokines, innate and adaptive immunity.Cellular signalling · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Kurt A ZimmermanDepartment of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama.
Jifeng HuangDivision of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Lan HeDivision of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Dustin Z RevellDepartment of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama.
Zhang LiDepartment of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama.
Jung-Shan HsuDivision of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Wayne R FitzgibbonDivision of Nephrology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.
E Starr HazardAcademic Affairs Faculty and Computational Biology Resource Center, Medical University of South Carolina, Charleston, South Carolina.
Gary HardimanSchool of Biological Sciences, Institute for Global Food Security, Queens University Belfast, Belfast, United Kingdom.
Michal MrugDivision of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
P Darwin BellDivision of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Bradley K YoderDepartment of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama.
Takamitsu SaigusaDivision of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.ORCID 0000-0002-2398-1572
University of Alabama at Birmingham · USMedical University of South Carolina · USQueen's University Belfast · GB
Funding
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Latesha Ellen Elopre · 1988 to 2026
$84.1MUAB-UCSD O'Brien Core Center for Acute Kidney Injury ResearchP30DK079337 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AGARWAL, ANUPAM · 2008 to 2022
$18.3MUAB Recessive PKD Research and Translational Core CenterP30DK074038 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI YODER, BRADLEY K. · 2005 to 2019
$16.6MIMMUNOLOGIC DISEASES AND BASIC IMMUNOLOGYT32AI007051 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Laurie Ellen Harrington · 1985 to 2026
$13.1MResearch BaseP30DK090868 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI WATNICK, TERRY J · 2010 to 2019
$11.1MROS Modulation of Innate and Adaptive Immunity in RAP30AR048311 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MOUNTZ, JOHN D · 2001 to 2017
$9.5MPKD Innovation and Resource Development CoreU54DK126114 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI Terry J Watnick · 2020 to 2026
$7.3MThe Genetic Basis of Opioid Dependence Vulnerablility in a Rodent ModelU01DA045300 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Christine Cheng, Dongjun Chung · 2018 to 2026
$6.1MCilia and Cystic Kidney DiseaseR01DK065655 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI YODER, BRADLEY K. · 2004 to 2017
$4.4MInjury Response Mediated Pathogenesis in Renal CiliopathiesR01DK115752 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Bradley K. Yoder · 2018 to 2026
$4.0MMechanisms of C3 effects in ARPKD pathogenesisR01DK097423 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MRUG, MICHAL · 2013 to 2017
$1.6MRenal Mechanism for Hypertension in Polycistic Kidney DiseaseK08DK106465 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SAIGUSA, TAKAMITSU · 2015 to 2019
$816kBLRD VA I01 BX002298BLRD VA I01 BX004232NIAID NIH HHS P30 AI027767NIAID NIH HHS T32 AI007051NIAMS NIH HHS P30 AR048311NIDA NIH HHS U01 DA045300NIDDK NIH HHS K08 DK106465NIDDK NIH HHS P30 DK074038NIDDK NIH HHS P30 DK079337NIDDK NIH HHS P30 DK090868NIDDK NIH HHS R01 DK065655NIDDK NIH HHS R01 DK097423NIDDK NIH HHS R01 DK115752NIDDK NIH HHS R03 DK119717NIDDK NIH HHS U54 DK126114
Abstract
backgroundAutosomal dominant polycystic kidney disease is caused by genetic mutations in
methodsIn these studies, we used conditional
resultsAnalyses of qRT-PCR and IRF5 ASO treatment significantly reduced macrophage numbers,
conclusionsThese data suggest that
Indexed as
Polycystic Kidney, Autosomal DominantPolycystic Kidney DiseasesAnimalsInterferon Regulatory FactorsKidneyMacrophagesMiceInterferon Regulatory FactorsIrf5 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.